GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Growth Rank

Ludwig Enterprises (Ludwig Enterprises) Growth Rank : 0 (As of Jun. 04, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Growth Rank?

Ludwig Enterprises has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Ludwig Enterprises Growth Rank Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.